CER 227185Alternative Names: CER227185
Latest Information Update: 11 May 2007
At a glance
- Originator Cerep
- Class Antineoplastics
- Mechanism of Action Cell cycle protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 11 May 2007 Discontinued - Phase-I/II for Acute myeloid leukaemia in France (PO)